Countervail Corporation

News

FDA agrees that Countervail’s non-human primate animal model is appropriate for the company’s Animal Rule pivotal GLP study testing

FDA agrees that Countervail’s non-human primate animal model is appropriate for the company’s Animal Rule pivotal GLP study testing. Following FDA review of Countervail’s submission of a justification for the use of the Cynomolgus macaque animal model, the FDA agreed with the model’s acceptability as related to submission under the Animal Rule. Countervail will be using this model for pivotal GLP testing of the company’s AverTox (galantamine hydrobromide) oral pre-treatment medical countermeasure product to counter nerve agent toxicity.